192 related articles for article (PubMed ID: 38114821)
21. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
24. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
[TBL] [Abstract][Full Text] [Related]
25. Antiemetic guidelines: Have we incorporated the changes concerning carboplatin and anthracyclines?
Redondo Capafons S; Soriano Gutierrez L; Dalmau Portulas E; Barragán Muñoz À; Martínez Robles S; Gómez-Valent M
Farm Hosp; 2023; 47(5):183-189. PubMed ID: 37268481
[TBL] [Abstract][Full Text] [Related]
26. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
[TBL] [Abstract][Full Text] [Related]
27. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Rapoport BL; Herrstedt J; Snow RC; Radhakrishnan V; Saito M; Navari RM; Smit T
Support Care Cancer; 2023 Dec; 32(1):36. PubMed ID: 38105286
[TBL] [Abstract][Full Text] [Related]
28. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).
Aapro M; Caprariu Z; Chilingirov P; Chrápavá M; Curca RO; Gales L; Grigorescu AC; Huszno J; Karlínová B; Kellnerová R; Malejčíková M; Marinca M; Petru E; Płużanski A; Pokorná P; Pribulova Z; Rubach M; Steger GG; Tesařová P; Valekova L; Yordanov N; Walaszkowska-Czyz A
Eur J Cancer; 2022 May; 166():126-133. PubMed ID: 35290913
[TBL] [Abstract][Full Text] [Related]
29. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
30. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
[TBL] [Abstract][Full Text] [Related]
31. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
32. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.
Jordan K; Blättermann L; Hinke A; Müller-Tidow C; Jahn F
Support Care Cancer; 2018 Jan; 26(1):21-32. PubMed ID: 28861627
[TBL] [Abstract][Full Text] [Related]
33. [Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?
Capafons SR; Gutierrez LS; Portulas ED; Muñoz ÀB; Robles SM; Gómez-Valent M
Farm Hosp; 2023; 47(5):T183-T189. PubMed ID: 37500396
[TBL] [Abstract][Full Text] [Related]
34. Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis.
Zhang Y; Hou X; Zhang R; Chen G; Huang Y; Yang Y; Zhao Y; Fang W; Hong S; Kang S; Zhou T; Zhang Z; Chen X; Zhang L
Future Oncol; 2018 Aug; 14(19):1933-1941. PubMed ID: 30019968
[TBL] [Abstract][Full Text] [Related]
35. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
36. [Prophylaxis of nausea and vomiting after medical cancer treatment : Guidelines on supportive treatment-Part II].
Link H
Urologie; 2022 Jun; 61(6):667-680. PubMed ID: 35925083
[TBL] [Abstract][Full Text] [Related]
37. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy induced emesis: pathophysiology and prevention].
Mailliez A; Bonneterre J
Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
[TBL] [Abstract][Full Text] [Related]
40. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
Jordan K; Warr DG; Hinke A; Sun L; Hesketh PJ
Support Care Cancer; 2016 May; 24(5):1941-1954. PubMed ID: 26476625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
